Novel oxo-pyridine compound, preparation method therefor, and use thereof
Patent Information
- Application Number
- MYPI2025003745
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-12-21
- Filing Date
- 2023-12-20
- Publication Date
- 2024-06-21
AI Technical Summary
Existing FXI inhibitors have problems such as high bleeding risk, complex pharmacokinetics, high price and difficulty in control in clinical application. Moreover, the pharmacokinetic changes of deuterated drugs are unpredictable, affecting the efficacy and safety.
Develop a new oxopyridine compound whose structure is designed to have excellent FXIa inhibitory effect and good pharmacokinetic characteristics through specific hydrogen/deuterium substitution and functional group combination, including specific compound structure and synthetic route, Forms compounds with potent anticoagulant effects.
It achieves stronger FXIa inhibitory effect, reduces the risk of bleeding, has better pharmacokinetic characteristics, higher safety and better drug efficacy, and some compounds with deuterated positions show rapid elimination and low toxicity.
Abstract
Description
Novel oxopyridine compounds and their preparation methods and uses
[0001] Related applications
[0002] This application claims priority to the invention patent filed on December 21, 2022, entitled "Novel oxopyridine compounds, preparation methods and uses thereof" and patent number CN202211647390.2, which is hereby expressly incorporated herein by reference. Technical Field
[0003] The present invention relates to the field of medicinal chemistry, and specifically to oxopyridine compounds or their salts and isomers, their preparation methods, and their use in preparing drugs for treating and / or preventing diseases associated with FXIa receptors, especially in preparing drugs for treating and / or preventing cerebrovascular arterial diseases and / or peripheral arterial diseases. Background Art
[0004] Thromboembolic disease is a condition in humans and animals caused by abnormal blood clots that form within blood vessels during life. Thrombosis is caused by three factors: vascular damage, blood changes, and blood flow stasis. It is a group of complications arising from many different diseases and causes. Due to differences in underlying diseases and the location of thromboembolism, thrombosis can clinically manifest as myocardial infarction, stroke, deep vein thrombosis (DVT), pulmonary embolism, atrial fibrillation, and cerebral infarction. Myocardial infarction, cerebral infarction, and pulmonary infarction, particularly those caused by embolism and infarction, are the leading causes of death, claiming nearly 12 million lives annually worldwide, nearly a quarter of the world's total death toll.
[0005] Coagulation factor XI (FXI) is a plasma serine protease essential for maintaining the intrinsic pathway. Upon activation, it generates activated coagulation factor XIa (FXIa), which plays a key role in the amplification of the coagulation cascade. During the coagulation cascade, thrombin can feedback activate FXI, which in turn stimulates the production of large amounts of thrombin, thereby amplifying the coagulation cascade. Therefore, drugs targeting FXI can block the intrinsic pathway and inhibit the amplification of the coagulation cascade, thereby exerting antithrombotic effects. Recent clinical data linking human factor XI (FXI) deficiency or elevated FXI levels with the development of thrombotic diseases, as well as experimental antithrombotic studies in animals with FXI deficiency, knockout, or inhibition, have demonstrated that FXI inhibition may reduce the risk of bleeding compared with direct FXa inhibitors, making it a novel target for antithrombotic prevention and treatment.
[0006] Reported FXI inhibitors mainly include monoclonal antibodies, antisense oligonucleotides, chemical small molecules, peptides or proteins and peptide mimetics. Currently, milvexian, jointly developed by BMS and Johnson & Johnson, has completed Phase II clinical trials, and the results show that it has a lower risk of bleeding. BMS's intravenous small molecule FXIa inhibitor BMS-962122 has completed Phase I clinical trials and has been suspended. ONO-7684, a small molecule oral FXIa inhibitor developed by Japan's Ono Biotechnology Co., Ltd., has entered Phase I clinical trials. Monoclonal antibodies and antisense oligonucleotides need to be injected, and have disadvantages such as high price, slow onset of effect and potential difficulty in control.
[0007] The efficacy, pharmacokinetics, and toxicity of drugs in vivo are influenced by numerous factors and exhibit corresponding complexity. Even slight changes in the chemical structure at any position can alter their efficacy, pharmacokinetics, and toxicity in vivo. For example, deuteration, compared to corresponding non-deuterated drugs, exhibits significant contingency and unpredictability in the pharmacokinetic and other properties of deuterated drugs. Deuteration at certain sites has been shown to extend the half-life, as seen in the marketed drugs donafenib tosylate and deuterated tetrabenazine. However, at other sites, rather than extending the half-life, it may even be shortened (Scott L. Harbeson, Roger D. Tung. Deuterium in Drug Discovery and Development, pp. 405-406). Furthermore, hydrogen atoms at certain positions on drug molecules are not easily deuterated due to steric hindrance and other factors. Therefore, the location of deuterated drugs is unpredictable.
[0008] Bayer's FXI inhibitor Asundexian has entered Phase III clinical trials with an average terminal half-life of up to 17.8 hours. Compared with apixaban, although it has certain advantages in bleeding risk, it still has a greater bleeding risk. Therefore, the development of new FXIa small molecule inhibitors with stronger activity, better absorption, relatively faster metabolism, lower bleeding risk and better safety can make up for the shortcomings of current clinical anticoagulant and antithrombotic drugs that are prone to bleeding complications and meet unmet clinical needs.
[0009] Summary of the Invention
[0010] The compound of the present invention is a novel oxopyridine compound. Most of the compounds in the examples show good anticoagulant effect and have strong FXIa inhibitory effect.
[0011] In one aspect, the present invention provides a compound represented by formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof:
[0012] in,
[0013] R 1 is selected from halogen or trifluoromethyl;
[0014] R 2 Independently selected from NH2, NHR 7 , OH or OR 8 , where: R 7 、R 8 is selected from alkyl or cycloalkyl, R 7 、R 8 The hydrogen in the atom can be replaced by one or more deuterium atoms;
[0015] R 3 、R 6 independently selected from hydrogen, halogen, alkoxy, haloalkyl or CONH2;
[0016] R 4 、R 5 independently selected from hydrogen, halogen, alkoxy or haloalkyl;
[0017] R 9 Independently selected from CH3 or CD3;
[0018] Among them, except the following compounds:
[0019] Furthermore, in the above compound, its stereoisomer or pharmaceutically acceptable salt, the R 1 selected from chloro or trifluoromethyl;
[0020] or / and R 2 Independently selected from NH2, NHR 7 ,OH,OR 8 , where: R 7 、R 8 is selected from methyl, ethyl, propyl, cyclopropyl, cyclopropylmethyl or tert-butyl, R 7 、R 8 The hydrogen in the atom can be replaced by one or more deuterium atoms;
[0021] or / and R 3 、R 6 independently selected from hydrogen, fluorine, chlorine, methoxy, trifluoromethyl or CONH2;
[0022] or / and R 4 、R 5 independently selected from hydrogen, fluorine, chlorine, methoxy or trifluoromethyl;
[0023] or / and R 9 Independently selected from CH3 or CD3.
[0024] Furthermore, in the above compound, its stereoisomer or pharmaceutically acceptable salt, the R1 Selected from trifluoromethyl;
[0025] or / and R 2 Independently selected from NH2, NHR 7 , OH or OR 8 , where: R 7 、R 8 is selected from methyl, ethyl, propyl, cyclopropyl, cyclopropylmethyl or tert-butyl, R 7 、R 8 The hydrogen in the atom can be replaced by one or more deuterium atoms;
[0026] or / and R 3 、R 6 independently selected from hydrogen, fluorine, chlorine, methoxy, trifluoromethyl or CONH2;
[0027] or / and R 4 、R 5 independently selected from hydrogen, fluorine or chlorine;
[0028] or / and R 9 Independently selected from CH3 or CD3.
[0029] Furthermore, in the above compound, its stereoisomer or pharmaceutically acceptable salt, the R 1 Selected from trifluoromethyl;
[0030] or / and R 2 Independently selected from NH2, NHCH3, NHCD3, OH, OCH3, OCD3 or OC(CH3)3;
[0031] or / and R 3 、R 6 independently selected from fluoro, chloro, methoxy or trifluoromethyl;
[0032] or / and R 4 、R 5 independently selected from hydrogen, fluorine or chlorine;
[0033] or / and R 9 Independently selected from CH3 or CD3.
[0034] Furthermore, the above compound, its stereoisomer or pharmaceutically acceptable salt comprises the following structure:
[0035] In the event of a conflict between the chemical nomenclature and the structural formula in the present invention, the compound structure represented by the number shall prevail.
[0036] Furthermore, hydrogen in the structure of the above-mentioned compound, its stereoisomer or pharmaceutically acceptable salt may be replaced by one or more deuterium.
[0037] Furthermore, deuterated compounds in which hydrogen in the structure of the above-mentioned compounds, stereoisomers or pharmaceutically acceptable salts thereof is replaced by one or more deuteriums include but are not limited to the above-mentioned Compound 28, Compound 29 and Compound 30.
[0038] In another aspect, the present invention provides a method for preparing the above-mentioned compound, its stereoisomers or pharmaceutically acceptable salts, comprising the following steps:
[0039] When R 2 NH2, NHR 7 OR 8 The synthetic route is as follows:
[0040] where R 1 、R 3 、R 4 、R 5 、R 6 、R 7 、R 8 、R 9 has the same meaning as any one of claims 1 to 6;
[0041] Step 1: The starting material a undergoes bromination reaction to generate intermediate b;
[0042] Step 2: Intermediate b undergoes a condensation reaction with starting material c to generate intermediate c;
[0043] Step 3: Intermediate d undergoes a substitution reaction with compound e to generate a compound of formula (1);
[0044] When R 2 When it is OH, the synthetic route is as follows:
[0045] where R 1 、R 3 、R 4 、R 5 、R 6 、R 7 、R 9 has the same meaning as any one of claims 1 to 6;
[0046] Step 4: Compound f undergoes hydrolysis under alkaline conditions to generate a compound of formula (1).
[0047] Furthermore, the present invention also provides a key intermediate, the structure of which is shown in the following formula e:
[0048] Among them, R 1 is selected from halogen or trifluoromethyl, R 9 Selected from CH3 or CD3; preferably, the R 1 is selected from halogen or trifluoromethyl, R 9 Selected from CD3.
[0049] Furthermore, the intermediate is selected from the following compounds:
[0050] 5-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-(methoxy-d3)pyridin-2(1H)-one;
[0051] 4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-5-(methoxy-d3)pyridin-2(1H)-one.
[0052] The above term "halogen" includes fluorine, chlorine, bromine or iodine; preferably fluorine, chlorine or bromine.
[0053] In a third aspect, the present invention provides a pharmaceutical composition comprising any one of the above-mentioned compounds, stereoisomers or pharmaceutically acceptable salts thereof, and the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
[0054] In a fourth aspect, the present invention further provides use of the above-mentioned compound, its stereoisomers or pharmaceutically acceptable salts in the preparation of drugs for treating and / or preventing diseases associated with FXIa receptors.
[0055] Furthermore, the aforementioned disease associated with FXIa receptor is selected from cerebrovascular arterial disease and / or peripheral arterial disease.
[0056] Furthermore, the above-mentioned diseases associated with FXIa receptors are selected from transient ischemic attack (TIA), ischemic stroke, including cardioembolic stroke: for example, stroke due to atrial fibrillation, non-cardioembolic stroke: for example, lacunar stroke, stroke due to large artery or small artery disease, or stroke due to undetermined cause, cryptogenic stroke, embolic stroke, embolic stroke of undetermined origin, or events of thrombotic and / or thromboembolic origin leading to stroke or TIA, and / or conditions of peripheral arteries leading to peripheral arterial disease, including peripheral arterial occlusion, acute limb ischemia, amputation, reocclusion and restenosis after intervention (such as angioplasty, stent implantation or surgery and bypass), and / or stent thrombosis.
[0057] The term "alkyl" in the present invention represents a C1-C16 straight-chain or branched saturated alkyl group. The same explanation shall apply to other alkyl moieties containing "alkyl" substituents.
[0058] Beneficial Effects: Compared to existing technologies, the compounds of the present invention exhibit superior in vitro anticoagulant effects, which are highly consistent with their in vitro inhibitory effects on FXIa. Furthermore, some of the Example compounds exhibit superior pharmacokinetic characteristics in rats after injection, such as Compounds 21, 25, 26, and 27, which exhibit superior AUC and Cmax, indicating improved efficacy. Furthermore, they exhibit rapid elimination, resulting in enhanced safety. DETAILED DESCRIPTION
[0059] The present invention will be further described in detail below in conjunction with embodiments and test examples. The embodiments and test examples of the present invention are only used to illustrate the technical solutions of the present invention and are not intended to limit the present invention. Any equivalent substitutions in the art made in accordance with the contents disclosed in the present invention shall fall within the scope of protection of the present invention.
[0060] The compounds of the present invention, their stereoisomers, or pharmaceutically acceptable salts thereof can be prepared by selecting the synthetic routes described in the examples. Conventional conditions for the reaction starting materials and reaction solvents can be adjusted based on the desired substituents or salt formation. These conditions can be implemented by those skilled in the art based on the disclosure of the present invention. Furthermore, column chromatography in the present invention, unless otherwise specified, refers to silica gel column chromatography. The elution solvent, unless otherwise specified, can be determined using a combination of the reaction solvent, common knowledge, or commonly used methods employed by those skilled in the art, to determine a single or mixed elution solvent.
[0061] The structure of the compound is determined by NMR ( 1 H NMR) or liquid chromatography-mass spectrometry (LC-MS).
[0062] The liquid chromatography-mass spectrometer (LC-MS) was Agilent G6120B (used with Agilent 1260 liquid chromatography); the nuclear magnetic resonance instrument ( 1 H NMR) was performed on a Bruker AVANCE-400 or Bruker AVANCE-800, and nuclear magnetic resonance ( 1 H NMR) shifts (δ) are given in parts per million (ppm) using DMSO as the solvent and tetramethylsilane (TMS) as the internal standard. Chemical shifts are expressed in 10 -6 The units are given in ppm.
[0063] The term "room temperature" in the present invention refers to a temperature between 10 and 30°C.
[0064] Example 1: Preparation of Compound 1
[0065] Step 1: (R)-2-Bromo-3-propionic acid
[0066] Take 5g (48.49mmol) of concentrated sulfuric acid and add it to 60ml of water. Cool it to below 5°C, add 23g (193.3mmol) of potassium bromide and 5g (48.49mmol) of D-2-aminobutyric acid, and dropwise add 5g (72.46mmol) of sodium nitrite dissolved in 30ml of water. Control the temperature below 0-5°C and add it over about 30 minutes. After the addition, stir and react at 0-5°C overnight. The next day, extract the reaction solution twice with ethyl acetate, combine the organic phases, wash the organic phases with water and saturated brine, dry them over anhydrous sodium sulfate, and evaporate the solvent to obtain 7.5g of oil, which is used directly in the next step without purification.
[0067] Step 2: Preparation of (R)-4-(2-bromobutyramide)-2-chlorobenzamide
[0068] 441 mg (2.64 mmol) of (R)-2-bromo-3-propionic acid was dissolved in 4 ml of tetrahydrofuran, and 300 mg (1.76 mmol) of 4-amino-2-chlorobenzamide was added. The mixture was cooled to below 0°C, and 654 mg (8.27 mmol) of pyridine was added dropwise. Then, 2.24 g (3.52 mmol) of 1-propylphosphoric anhydride (50% ethyl acetate solution) diluted in 2 ml of tetrahydrofuran was added dropwise. After addition, the mixture was stirred at 0-5°C for 10 minutes and then at room temperature for 30 minutes. After completion of the reaction, water was added to terminate the reaction, and EA was added for extraction. The organic phase was washed sequentially with 5% citric acid, saturated sodium bicarbonate, water, and saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated to dryness to yield 540 mg of crude product. 5 ml of ethyl acetate was added to the crude product, and the mixture was stirred at room temperature for 2 hours. The mixture was filtered, and the filter cake was washed with ethyl acetate and dried under vacuum to yield 430 mg of a white solid with a yield of 76.4% and a purity of 96.55%.
[0069] ESI-MS: m / z = 319.0 (M+H) + .
[0070] Step 3: Preparation of title compound 1
[0071] To a solution of 200 mg (0.539 mmol) of 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxypyridin-2(1H)-one, 5 ml of isopropanol, and 2 ml of acetone was added 187 mg (1.624 mmol) of tetramethylguanidine, stirred for 5 minutes, and then 207 mg (0.648 mmol) of (R)-4-(2-bromobutyramide)-2-chlorobenzamide was added. The mixture was stirred at room temperature overnight. Upon completion, the reaction was terminated by addition of saturated ammonium chloride and extracted with ethyl acetate. The organic phase was washed sequentially with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent evaporated to dryness to yield 400 mg of crude product. The product was purified by column chromatography using an eluent of ethyl acetate:petroleum ether = 1:2 to yield 245 mg of a white solid. The yield was 74.6% and the purity was 96.20%.
[0072] ESI-MS: m / z = 609.1 (M+H) + .
[0073] 1 H NMR (400MHz, DMSO-d6)δ:10.67(s,1H),9.14(d,1H),7.98-7.72(m,5H),7.60-7.30(m,3H),7.13(s,1H),6.53(s,1H),5.51(dd 1H),3.25(s,3H),2.14-2.04(m,2H),0.78(t,3H).
[0074] Example 2: Preparation of Compound 2
[0075] Step 1: Preparation of (S)-methyl 2-chloro-4-(2-(4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxy-2-oxopyridin-1(2H)-yl)butanamido)benzoate
[0076] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by methyl 4-amino-2-chlorobenzoate to obtain the title compound with a purity of 96.20%.
[0077] ESI-MS: m / z = 624.1 (M+H) + .
[0078] Step 2: Preparation of title compound 2
[0079] To 250 mg (0.40 mmol) of methyl (S)-2-chloro-4-(2-(4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxy-2-oxopyridin-1(2H)-yl)butanamido)benzoate was added 5 ml of methanol and heated to 50°C. 51 mg (1.215 mmol) of lithium hydroxide monohydrate dissolved in 2.5 ml of water was added and stirred at 50°C for 1 hour. After the reaction was complete, 5% aqueous citric acid was added to terminate the reaction. Ethyl acetate was added for extraction, and the organic phase was washed sequentially with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated to dryness to yield 245 mg of crude product. 5 ml of ethyl acetate was added and stirred at room temperature for 2 hours. The mixture was filtered, and the filter cake was washed with ethyl acetate. The filter cake was dried under vacuum to yield 200 mg of a white solid with a yield of 81.9% and a purity of 97.89%.
[0080] ESI-MS: m / z = 610.1 (M+H) + .
[0081] 1 H NMR(400MHz, DMSO-d6)δ:12.88(s,1H),10.89(s,1H),9.19(s,1H),8.05-7.88(m,3H),7.69-7.36(m,3H),7.28(s,1H),6.55(s,1H),5.58(dd 1H),3.28(s,3H),2.15-2.03(m,2H),0.76(t,3H).
[0082] Example 3: Preparation of Compound 3
[0083] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-2-chloro-N-methylbenzamide to obtain the title compound 3 with a purity of 96.80%.
[0084] ESI-MS: m / z = 623.1 (M+H) + .
[0085] 1 H NMR (400MHz, DMSO-d6)δ:10.58(s,1H),9.11(s,1H),7.91-7.66(m,4H),7.58-7.25(m,3H),7.15(s,1H),6.51(s,1H),5.53(dd 1H),3.26(s,3H),2.88(d,3H),2.12-2.01(m,2H),0.79(t,3H).
[0086] Example 4: Preparation of Compound 4
[0087] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-2-chloro-benzoic acid methyl ester to obtain the title compound 4 with a purity of 97.90%.
[0088] ESI-MS: m / z = 624.1 (M+H) + .
[0089] 1 H NMR (400MHz, DMSO-d6)δ:10.53(s,1H),9.18(s,1H),7.91-7.75(m,3H),7.56-7.25(m,3H),7.16(s,1H),6.50(s,1H),5.56(dd 1H),4.10(s,3H),3.28(s,3H),2.18-2.07(m,2H),0.79(t,3H).
[0090] Example 5: Preparation of Compound 5
[0091] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-2-methoxybenzamide to obtain the title compound 5 with a purity of 97.95%.
[0092] ESI-MS: m / z = 605.2 (M+H) + .
[0093] 1 H NMR(400MHz,DMSO-d6)δ:10.68(s,1H),9.14(d,1H),7.95-7.73(m,4H),7.56(m,2H),7.46(d,1H),7.19(d d,1H),7.14(s,1H),6.53(s,1H),5.54(dd,1H),3.86(s,3H),3.25(s,3H),2.16-2.04(m,2H),0.78(t,3H).
[0094] Example 6: Preparation of Compound 6
[0095] Step 1: Preparation of (S)-methyl 4-(2-(4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxy-2-oxopyridin-1(2H)-yl)butanamido)-2-methoxybenzoate
[0096] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced with 4-amino-2-methoxy-benzoic acid methyl ester to obtain the title compound with a purity of 97.20%. ESI-MS: m / z = 620.0 (M+H) + .
[0097] Step 2: Preparation of title compound 6
[0098] To 250 mg (0.403 mmol) of methyl (S)-4-(2-(4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxy-2-oxopyridin-1(2H)-yl)butanamido)-2-methoxybenzoate was added 6 ml of methanol and 68 mg (1.62 mmol) of lithium hydroxide monohydrate dissolved in 3 ml of water. The mixture was stirred at 60°C for 1 hour. After completion of the reaction, the mixture was cooled to room temperature and terminated by the addition of 5% aqueous citric acid. The mixture was extracted with ethyl acetate, and the organic phase was washed sequentially with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated to dryness to yield 250 mg of crude product. The product was purified by column chromatography using a solvent of dichloromethane:methanol = 50:1. The target product was collected to yield 198 mg of a white solid, with a yield of 81.1% and a purity of 97.66%.
[0099] ESI-MS: m / z = 606.1 (M+H) + .
[0100] 1 H NMR(400MHz,DMSO-d6)δ:12.35(s,1H),10.68(s,1H),9.14(d,1H),7.93-7.75(m,3H),7.68(d,1H),7.54(d,1 H),7.22-7.10(m,2H),6.54(s,1H),5.54(dd,1H),3.78(s,3H),3.25(s,3H),2.14-2.04(m,2H),0.79(t,3H).
[0101] Example 7: Preparation of Compound 7
[0102] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-2-trifluoromethyl-benzamide to obtain the title compound 7 with a purity of 95.21%.
[0103] ESI-MS: m / z = 643.1 (M+H) + .
[0104] 1H NMR(400MHz,DMSO-d6)δ:10.80(s,1H),9.13(s,1H),8.12(d,1H),8.02-7.72(m,5H),7.54-7.5 1(m,2H),7.14(s,1H),6.54(s,1H),5.51(dd,1H),3.25(s,3H),2.23-2.03(m,2H),0.79(t,3H).
[0105] Example 8: Preparation of Compound 8
[0106] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-1,2-dibenzamide to obtain the title compound 8 with a purity of 98.69%.
[0107] ESI-MS: m / z = 618.2 (M+H) + .
[0108] 1 H NMR(400MHz, DMSO-d6)δ:11.09(s,1H),9.20(s,1H),8.28-7.96(m,5H),7.85-7.59(m,5H),7.28(s,1H),6.96(s,1H),5.98(dd 1H),3.29(s,3H),2.23-2.15(m,2H),0.80(t,3H).
[0109] Example 9: Preparation of Compound 9
[0110] The preparation method was the same as that of Example 2, except that 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxypyridin-2(1H)-one was replaced with 4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxypyridin-2(1H)-one to obtain the title compound 9 with a purity of 97.25%.
[0111] ESI-MS: m / z = 576.1 (M+H) + .
[0112] 1H NMR (400MHz, DMSO-d6)δ:12.88(s,1H),10.89(s,1H),9.19(s,1H),8.01-7.85(m,3H),7.68-7.32(m,3H),7.25(s,1H),6.53(s,1H),5.59(dd 1H),3.27(s,3H),2.16-2.02(m,2H),0.77(t,3H).
[0113] Example 10: Preparation of Compound 10
[0114] The preparation method was the same as that of Example 1, except that 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxypyridin-2(1H)-one in step 3 was replaced with 4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxypyridin-2(1H)-one to obtain the title compound 10 with a purity of 98.14%.
[0115] ESI-MS: m / z = 575.1 (M+H) + .
[0116] 1 H NMR (400MHz, DMSO-d6)δ:10.70(s,1H),9.15(d,1H),7.97-7.71(m,5H),7.59-7.28(m,3H),7.15(s,1H),6.54(s,1H),5.52(dd 1H),3.28(s,3H),2.15-2.03(m,2H),0.78(t,3H).
[0117] Example 11: Preparation of Compound 11
[0118] The preparation method is the same as that of Example 7, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-2-trifluoromethyl-benzamide, and 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxypyridin-2(1H)-one in step 3 is replaced by 4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxypyridin-2(1H)-one to obtain the title compound 11 with a purity of 97.46%.
[0119] ESI-MS: m / z = 609.1 (M+H) + .
[0120] 1H NMR(400MHz,DMSO-d6)δ:10.79(s,1H),9.11(s,1H),8.10(d,1H),8.00-7.69(m,5H),7.56-7.5 3(m,2H),7.18(s,1H),6.56(s,1H),5.53(dd,1H),3.28(s,3H),2.21-2.00(m,2H),0.77(t,3H).
[0121] Example 12: Preparation of Compound 12
[0122] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-2,3-difluoro-benzamide to obtain the title compound 12 with a purity of 98.27%.
[0123] ESI-MS: m / z = 611.1 (M+H) + .
[0124] 1 H NMR(400MHz, DMSO-d6)δ:10.57(s,1H),9.15(s,1H),7.88-7.81(m,2H),7.79(d,J=2.1Hz,2H),7.71(d,J=9.1Hz,2H),7.5 3-7.37(m,1H),7.10(s,1H),6.55(s,1H),5.68(s,1H),3.24(s,3H),2.11(dt,J=17.0,8.6Hz,2H),0.79(t,J=7.2Hz,3H).
[0125] Example 13: Preparation of Compound 13
[0126] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-3-fluoro-benzamide to obtain the title compound 13 with a purity of 98.64%.
[0127] ESI-MS: m / z = 593.1 (M+H) + .
[0128] 1H NMR (400MHz, DMSO-d6) δ: 10.41 (s, 1H), 9.15 (d, J = 1.0Hz, 1H), 8.05-7.93 (m, 2H), 7.88-7.81 (m, 2H), 7.80-7.78 (m, 1H), 7.7 8-7.67(m,2H),7.47(s,1H),7.11(s,1H),6.54(s,1H),5.71(s,1H),3.24(s,3H),2.25-1.95(m,2H),0.78(t,J=7.2Hz,3H).
[0129] Example 14: Preparation of Compound 14
[0130] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-3,5-difluoro-benzamide to obtain the title compound 14 with a purity of 98.76%.
[0131] ESI-MS: m / z = 611.1 (M+H) + .
[0132] 1 H NMR(400MHz, DMSO-d6)δ:10.37(s,1H),9.13(s,1H),8.13(s,1H),7.87-7.80(m,2H),7.78(d,J=2.0Hz,1H),7.69(s,1H ),7.64(d,J=8.6Hz,2H),7.07(s,1H),6.56(s,1H),5.65(s,1H),3.22(s,3H),2.15-1.95(m,2H),0.81(t,J=7.2Hz,3H).
[0133] Example 15: Preparation of Compound 15
[0134] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-3,5-dichlorobenzamide to obtain the title compound 15 with a purity of 98.12%.
[0135] ESI-MS: m / z = 643.1 (M+H) + .
[0136] 1H NMR(400MHz,DMSO-d6)δ:10.37(s,1H),9.13(s,1H),8.13(s,1H),7.92-7.88(m,2H),7.82-7.78(m,1H),7.69(s,1H ),7.66-7.62(m,2H),7.07(s,1H),6.56(s,1H),5.65(s,1H),3.22(s,3H),2.18-1.98(m,2H),0.81(t,J=7.2Hz,3H).
[0137] Example 16: Preparation of Compound 16
[0138] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-3-chlorobenzamide to obtain the title compound 16 with a purity of 98.48%.
[0139] ESI-MS: m / z = 609.1 (M+H) + .
[0140] 1 H NMR(400MHz,DMSO-d6)δ:10.08(s,1H),9.16(s,1H),8.07(s,1H),8.00(s,1H),7.84(m,4H),7.79(d,J=2.1Hz,1 H),7.50(s,1H),7.10(s,1H),6.57(s,1H),5.69(s,1H),3.24(s,3H),2.28-2.03(m,2H),0.80(t,J=7.2Hz,3H).
[0141] Example 17: Preparation of Compound 17
[0142] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-2-fluoro-N-methylbenzamide to obtain the title compound 17 with a purity of 97.95%.
[0143] ESI-MS: m / z = 607.1 (M+H) + .
[0144] 1H NMR (400MHz, DMSO-d6) δ: 10.83 (s, 1H), 9.14 (d, J = 1.1Hz, 1H), 8.13-8.06 ( m,1H),7.89-7.80(m,2H),7.79(d,J=2.0Hz,1H),7.70-7.60(m,2H),7.37( dd,J=8.5,2.0Hz,1H),7.13(s,1H),6.54(s,1H),5.52(t,J=7.8Hz,1H),3. 25(s,3H),2.76(d,J=4.6Hz,3H),2.18-2.02(m,2H),0.78(t,J=7.2Hz,3H).
[0145] Example 18: Preparation of Compound 18
[0146] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-2-methoxy-N-methylbenzamide to obtain the title compound 18 with a purity of 96.25%.
[0147] ESI-MS: m / z = 619.2 (M+H) + .
[0148] 1 H NMR (400MHz, DMSO-d6) δ: 10.72 (s, 1H), 9.14 (d, J = 1.1Hz, 1H), 8.13-8.06 (m, 1 H),7.89-7.80(m,2H),7.79(d,J=2.0Hz,1H),7.70-7.60(m,2H),7.37(dd,J=8 .5,2.0Hz,1H),7.13(s,1H),6.54(s,1H),5.52(t,J=7.8Hz,1H),3.86(s,3H), 3.25(s,3H),2.76(d,J=4.6Hz,3H),2.18-2.02(m,2H),0.78(t,J=7.2Hz,3H).
[0149] Example 19: Preparation of Compound 19
[0150] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-3-fluoro-N-methylbenzamide to obtain the title compound 19 with a purity of 98.20%.
[0151] ESI-MS: m / z = 607.1 (M+H) + .
[0152] 1H NMR(400MHz, DMSO-d6)δ:10.40(s,1H),9.15(d,J=1.0Hz,1H),8.49(d,J=4.6Hz,1H), 7.98(t,J=8.1Hz,1H),7.89-7.80(m,2H),7.79(dd,J=2.1,0.7Hz,1H),7.71(dd,J=11. 8,1.9Hz,1H),7.66(dd,J=8.4,2.0Hz,1H),7.11(s,1H),6.54(s,1H),5.70(s,1H),3. 24 (s, 3H), 2.77 (d, J = 4.5Hz, 3H), 2.12 (dt, J = 15.2, 7.5Hz, 2H), 0.78 (t, J = 7.1Hz, 3H).
[0153] Example 20: Preparation of Compound 20
[0154] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-2,5-difluoro-N-methylbenzamide to obtain the title compound 20 with a purity of 98.20%.
[0155] ESI-MS: m / z = 625.1 (M+H) + .
[0156] 1 H NMR (400MHz, DMSO-d6) δ: 10.85 (s, 1H), 9.14 (d, J = 1.1Hz, 1H), 8.55 (q, J = 4.6Hz, 1H), 7.88-7.81 (m, 2H), 7.80-7.76 (m, 1H), 7.36 (d, J = 9. 8Hz, 2H), 7.12 (s, 1H), 6.54 (s, 1H), 5.48 (s, 1H), 3.25 (s, 3H), 2.75 (d, J = 4.6Hz, 3H), 2.08 (tt, J = 16.0, 8.4Hz, 2H), 0.78 (t, J = 7.2Hz, 3H).
[0157] Example 21: Preparation of Compound 21
[0158] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-2-fluorobenzamide, and 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxypyridin-2 (1H)-one in step 3 is replaced by 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-(methoxy-d3)pyridin-2 (1H)-one to obtain the title compound 21 with a purity of 97.65%.
[0159] ESI-MS: m / z = 596.2 (M+H) + .
[0160] 1 H NMR(400MHz, DMSO-d6)δ:10.79(s,1H),9.14(d,J=1.0Hz,1H),7.89-7.81(m,2H),7.79(dd,J=2.1,0.7Hz,1H),7.74-7.60(m,2H),7. 55(d,J=11.3Hz,2H),7.37(dd,J=8.6,2.0Hz,1H),7.13(s,1H),6.54(s,1H),5.53(s,1H),2.16-2.05(m,2H),0.78(t,J=7.2Hz,3H).
[0161] The structural confirmation data of the intermediate in step 3: 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-(methoxy-d3)pyridin-2(1H)-one are as follows:
[0162] ESI-MS: m / z = 374.1 (M+H) + .
[0163] 1 H NMR (400MHz, DMSO-d6) δ: 1H NMR (400MHz, DMSO-d6) δ: 11.21 (s, 1H), 9.18 (s, 1H), 7.81 (s, 2H), 7.72 (s, 1H), 695 (s, 1H), 6.41 (s, 1H).
[0164] Example 22: Preparation of Compound 22
[0165] The preparation method is the same as that of Example 1, except that 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxypyridin-2(1H)-one in step 3 is replaced with 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-(methoxy-d3)pyridin-2(1H)-one to obtain the title compound 22 with a purity of 97.65%.
[0166] ESI-MS: m / z = 612.1 (M+H) + .
[0167] 1 H NMR(400MHz, DMSO-d6)δ:10.79(s,1H),9.14(d,J=1.0Hz,1H),7.97-7.79(m,2H),7.79(dd,J=2.1,0.7Hz,1H),7.74-7.60(m,2H),7. 55(d,J=11.3Hz,2H),7.37(dd,J=8.6,2.0Hz,1H),7.13(s,1H),6.54(s,1H),5.53(s,1H),2.16-2.05(m,2H),0.78(t,J=7.2Hz,3H).
[0168] Example 23: Preparation of Compound 23
[0169] The preparation method is the same as the preparation method in Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-3-fluorobenzamide, and 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxypyridin-2(1H)-one in step 3 is replaced by 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-(methoxy-d3)pyridin-2(1H)-one to obtain the title compound 23 with a purity of 97.65%.
[0170] ESI-MS: m / z = 596.2 (M+H) + .
[0171] 1H NMR(400MHz, DMSO-d6)δ:10.41(s,1H),9.15(d,J=1.0Hz,1H),8.05-7.93(m,2H),7.88-7.81(m,2H),7.80-7.78(m,1 H),7.78-7.67(m,2H),7.47(s,1H),7.11(s,1H),6.54(s,1H),5.71(s,1H),2.25-1.95(m,2H),0.78(t,J=7.2Hz,3H).
[0172] Example 24: Preparation of Compound 24
[0173] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-3-fluoro-N-methylbenzamide, and 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxypyridin-2(1H)-one in step 3 is replaced by 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-(methoxy-d3)pyridin-2(1H)-one to obtain the title compound 24 with a purity of 97.65%.
[0174] ESI-MS: m / z = 610.2 (M+H) + .
[0175] 1 H NMR (400MHz, DMSO-d6) δ: 10.40 (s, 1H), 9.15 (d, J = 1.0Hz, 1H), 8.49 (d, J = 4.6Hz, 1 H),7.98(t,J=8.1Hz,1H),7.89-7.80(m,2H),7.79(dd,J=2.1,0.7Hz,1H),7.71(dd ,J=11.8,1.9Hz,1H),7.66(dd,J=8.4,2.0Hz,1H),7.11(s,1H),6.54(s,1H),5.70( s, 1H), 2.77 (d, J = 4.5Hz, 3H), 2.12 (dt, J = 15.2, 7.5Hz, 2H), 0.78 (t, J = 7.1Hz, 3H).
[0176] Example 25: Preparation of Compound 25
[0177] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-2-fluoro-N-methylbenzamide, and 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxypyridin-2(1H)-one in step 3 is replaced by 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-(methoxy-d3)pyridin-2(1H)-one to obtain the title compound 25 with a purity of 98.85%.
[0178] ESI-MS: m / z = 610.2 (M+H) + .
[0179] 1 H NMR(400MHz, DMSO-d6)δ:10.80(s,1H),9.20-9.08(m,1H),8.10(q,J=4.2Hz,1H),7.93-7.81(m,2H),7.78(d,J=2.1Hz,1H),7.70-7.58(m,2H), 7.37(dd,J=8.6,2.0Hz,1H),7.13(s,1H),6.54(s,1H),5.52(s,1H),2.76(d,J=4.6Hz,3H),2.20-2.02(m,J=7.6Hz,2H),0.78(t,J=7.2Hz,3H).
[0180] Example 26: Preparation of Compound 26
[0181] The preparation method is the same as that of Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-2-fluoro-N-(methyl-d3)benzamide to obtain the title compound 26 with a purity of 99.12%.
[0182] ESI-MS: m / z = 610.2 (M+H) + .
[0183] 1H NMR(400MHz, DMSO-d6)δ:10.79(s,1H),9.14(d,J=1.1Hz,1H),8.06(d,J=3.4Hz,1H),7.92-7.81(m,2H),7.81-7.76(m,1H),7.70-7.60(m,2H), 7.37(dd,J=8.6,2.0Hz,1H),7.13(s,1H),6.54(s,1H),5.51(d,J=8.6Hz,1H),3.25(s,3H),2.19-1.99(m,J=7.1Hz,2H),0.78(t,J=7.2Hz,3H).
[0184] Example 27: Preparation of Compound 27
[0185] The preparation method is the same as the preparation method in Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-2-fluoro-N-(methyl-d3)benzamide, and 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxypyridine-2(1H)-one in step 3 is replaced by 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-(methoxy-d3)pyridine-2(1H)-one to obtain the title compound 27 with a purity of 98.07%.
[0186] ESI-MS: m / z = 613.2 (M+H) + .
[0187] 1 H NMR(400MHz, DMSO-d6)δ:10.79(s,1H),9.14(d,J=1.1Hz,1H),8.06(d,J=3.4Hz,1H),7.90-7.76(m,3H),7.71-7.60(m, 2H), 7.37 (dd, J = 8.6, 2.0Hz, 1H), 7.13 (s, 1H), 6.54 (s, 1H), 5.52 (s, 1H), 2.09 (h, J = 7.1Hz, 2H), 0.78 (t, J = 7.2Hz, 3H).
[0188] Example 28: Preparation of Compound 28
[0189] The preparation method is the same as that of Example 1, except that the D-2-aminobutyric acid in step 1 is replaced by (R)-2-aminobutyric-3,3,4,4,4-d5 acid, and the 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-2-fluoro-benzamide to obtain the title compound 28 with a purity of 97.36%.
[0190] ESI-MS: m / z = 598.2 (M+H) + .
[0191] 1 H NMR (400MHz, DMSO-d6) δ: 10.72 (s, 1H), 9.10 (d, 1H), 7.98-7.74 (m, 5H), 7.62-7.36 (m, 3H), 7.11 (s, 1H), 6.56 (s, 1H), 5.50 (dd 1H), 3.26 (s, 3H).
[0192] Example 29: Preparation of Compound 29
[0193] The preparation method is the same as the preparation method in Example 1, except that 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-2-fluoro-benzamide, and 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxypyridin-2(1H)-one in step 3 is replaced by 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl-3,4,6-d3)-5-(methoxy)pyridin-2(1H)-one to obtain the title compound 29 with a purity of 97.66%.
[0194] ESI-MS: m / z = 596.2 (M+H) + .
[0195] 1 H NMR(400MHz, DMSO-d6)δ:10.80(s,1H),9.15(d,1H),7.92–7.82(m,2H),7.77(d,J=2.1Hz,1H),7.72–7.62(m, 2H), 7.13 (s, 1H), 6.54 (s, 1H), 5.52 (s, 1H), 3.28 (s, 3H), 2.21–2.03 (m, J = 7.6Hz, 2H), 0.79 (t, J = 7.2Hz, 3H).
[0196] Example 30: Preparation of Compound 30
[0197] The preparation method is the same as the preparation method in Example 1, except that the D-2-aminobutyric acid in step 1 is replaced by (R)-2-aminobutyric acid-3,3,4,4,4-d5 acid, the 4-amino-2-chlorobenzamide in step 2 is replaced by 4-amino-2-fluoro-N-(methyl-d3)benzamide, and the 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxypyridin-2(1H)-one in step 3 is replaced by 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-(methoxy-d3)pyridin-2(1H)-one to obtain the title compound 30 with a purity of 98.62%.
[0198] ESI-MS: m / z = 618.2 (M+H) + .
[0199] 1 H NMR(400MHz, DMSO-d6)δ:10.78(s,1H),9.16(d,J=1.1Hz,1H),8.06(d,J=3.4Hz,1H),7.92-7.78 (m,3H),7.71-7.60(m,2H),7.37(dd,J=8.6,2.0Hz,1H),7.13(s,1H),6.54(s,1H),5.52(s,1H).
[0200] Comparative Example 1: Preparation of (S)-4-(2-(4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-methoxy-2-oxopyridin-1(2H)-yl)butyramido)-2-fluorobenzamide
[0201] It was synthesized according to the method described in patent CN108026072B, with a purity of 98.5%.
[0202] ESI-MS: m / z = 593.1 (M+H) + .
[0203] 1 H NMR(400MHz,DMSO-d6)δ:10.78(s,1H),9.14(s,1H),7.88-7.77(m,3H),7.72-7.61(m,2H),7.55(d,2H) ),7.37(dd,1H),7.13(s,1H),6.54(s,1H),5.52(dd,1H),3.25(s,3H),2.18-2.00(m,2H),0.78(t,3H).
[0204] Test Example 1: Determination of the anticoagulant effect of human plasma in vitro
[0205] 1. Test samples
[0206] Example compounds 1 to 30 and comparative example 1.
[0207] 2. Test methods
[0208] Use sodium citrate (1:9) anticoagulant tubes to collect blood from healthy individuals, immediately mix it thoroughly with the anticoagulant, and centrifuge it at 4000 r / min at room temperature for 15 minutes. After centrifugation, use a pipette to draw the plasma sample and freeze it (-80℃) for later use.
[0209] Weigh an appropriate amount of compound and prepare a 10-100 mM stock solution with 100% DMSO (the specific stock solution concentration depends on the properties of the compound). Then, prepare working solutions of different concentrations (specifically: 1, 3, and 10 μM) using healthy human plasma as the solution and mix thoroughly. Incubate at 37°C for 3 minutes and perform APTT measurement on a CS-2000I instrument.
[0210] 3. Data Processing
[0211] GraphPad Prism software was used for analysis, and the APTT prolongation rate at each concentration was calculated.
[0212] 4. Test results
[0213] The results are shown in the table below. The APTT prolongation rates of the tested compounds 1, 2, 5, 6, 13, 17, 21, 25, 26, and 27 at 1 μM are all better than those of the compound in Comparative Example 1, and the APTT prolongation rates are greater than 50%. The test results estimate that the EC150 of the above inventive compounds is less than 1 μM.
[0214] Table 1 Results of in vitro anticoagulant effect test of human plasma
[0215] Test Example 2: Determination of coagulation factor FXIa inhibitor activity
[0216] 1. Test samples
[0217] Example compounds and comparative example 1.
[0218] 2. Experimental steps
[0219] 1) Prepare assay buffer (50 mM HEPES, 5 mM KCl, 145 mM NaCl, 1 mg / ml PEG 8000, pH 7.4) and equilibrate to room temperature;
[0220] 2) Prepare 10X compound working solution;
[0221] 3) Prepare 0.8 nM human FXIa working solution (2X), mix well and set aside;
[0222] 4) Add 20 μL of the FXIa working solution from step 3) to all experimental wells of a 384-well plate (Coring, 3702) and centrifuge at 200 g for 10 seconds at room temperature.
[0223] 5) Add 4 μL of the compound working solution from step 2) to the corresponding experimental wells in a 384-well plate, centrifuge at 200g, RT for 10 seconds, and then incubate the working plate at 25°C for 20 minutes;
[0224] 6) Prepare 750 μM S-2366 working solution (2.5X), mix well and set aside;
[0225] 7) Add 16 μL of the S-2366 working solution from step 6) to all experimental wells in a 384-well plate, centrifuge at 200g for 10 seconds at room temperature, and then incubate the plate at 37°C for 45 minutes.
[0226] 8) After incubation, the absorbance value at OD405 nm was read using EnVision and the data was collected.
[0227] 3. Data Analysis
[0228] 1) Z'factor=1-3*(SD Max +SD Min ) / (Mean Max -Mean Min );
[0229] 2)CV Max =(SD Max / Mean Max )*100%;
[0230] 3)CVMin=(SD Min / Mean Min )*100%;
[0231] 4) S / B = Single / Background;
[0232] 5) Blank control: 0.1% DMSO; Positive control: Comparative Example 1;
[0233] 6)IC 50 Calculation formula: Y=Bottom+(Top-Bottom) / (1+10^((LogIC 50 -X)*HillSlope))
[0234] X: log value of compound concentration; Y: inhibition rate (%).
[0235] Concentration setting: 5 concentrations, namely: 200nM, 40nM, 8nM, 1.6nM, 0.32nM, detection IC 50 value.
[0236] 4. Test results
[0237] The test results are shown in the following table: The tested compounds of the present invention all have a significant in vitro inhibitory effect on FXIa, and the inhibitory effects of compounds 2, 6, 17, 21, 25, 26, and 27 of the present invention on FXIa are stronger than those of the compound in comparative example 1, especially compounds 2 and 6. The other tested compounds of the present invention have an inhibitory effect on FXIa comparable to that of the comparative example.
[0238] Table 2 Determination of coagulation factor FXIa inhibitor activity
[0239] Test Example 3: Pharmacokinetic Study in Rats
[0240] 1. Test samples
[0241] Comparative Example 1 and Example Compounds 2, 6, 21, 25, 26, 27, and 28.
[0242] 2. Test operation
[0243] The experiment used 48 SD rats, all male, divided into 8 groups, 6 rats in each group, namely control group 1, compound group 2, compound group 6, compound group 21, compound group 25, compound group 26, compound group 27, and compound group 28. The rats were fasted for 12 hours before administration and had free access to water. Each group was given an oral gavage dose of 30 mg / kg.
[0244] Before dosing, blank blood was collected. After dosing, blood was collected at predetermined time points: 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 5 hours, 7 hours, and 24 hours. Approximately 0.5 mL of blood was collected and placed in an EDTA-K2 tube. Plasma was separated by centrifugation and stored at -80°C. Liquid chromatography-mass spectrometry (LC-MS / MS) was used to measure drug plasma concentrations. Based on the plasma concentration data, DAS 2.0 software was used to calculate pharmacokinetic parameters, including AUC0-t, Cmax, Tmax, and t1 / 2.
[0245] 3. Test results
[0246] The experimental results of the pharmacokinetic study of oral administration in rats are shown in the following table. Compared with the comparative example 1, the example compounds 2, 6, 21, 25, 26, and 27 have better absorption, AUC (0-t) In particular, the AUC and Cmax of Compound 21, Compound 25, Compound 26, and Compound 27 were significantly improved compared with Comparative Example 1 at the same dosage, indicating that the same pharmacological efficacy was achieved with a lower dosage of the compounds in this example.
[0247] At the same time, compared with Comparative Example 1 and Compound 28, Compound 21, Compound 25, Compound 26, and Compound 27 have shorter half-lives and have rapid elimination pharmacokinetic characteristics, indicating that their potential safety risks of bleeding are also lower, and also prove that not all deuterated positions have the effect of extending half-life. In particular, the present invention unexpectedly found that the general structure (1) containing R 9 and / or R 2 Deuterated compounds at the 3 position have more advantageous pharmacokinetic results.
[0248] Table 3 Pharmacokinetic results
[0249] Test Example 4: Effects of continuous drug administration on general condition and food intake in rats
[0250] 1. Trial Drug
[0251] Comparative Example 1 and Example Compound 2, Compound 21, Compound 25, Compound 26, and Compound 27.
[0252] 2. Experimental Plan
[0253] 70 healthy adult SD rats were randomly divided into 7 groups, half male and half female in each group, and divided into blank group, comparative example 1 group, compound 2 group, compound 21 group, compound 25 group, compound 26 group, and compound 27 group, with 10 rats in each group. The drugs were administered orally by gavage. The dosing schedule is shown in the table below. The drugs were administered once a day for 14 consecutive days. The blank group was given the same volume of solvent. After administration, the effects of the drugs on the general condition and food intake of the rats were observed and recorded.
[0254] Table 4 Continuous dosing regimen
[0255] 3. Test results
[0256] In the study of the general condition of rats after continuous oral administration for 14 days, more than 1 / 3 of the rats in the control group 1 showed piloerection and hypoactivity; no obvious abnormalities were found in the other groups.
[0257] The food intake observation results of rats in each group after continuous oral administration for 14 days are shown in the table below.
[0258] Table 5 Observation results of rat food intake (within 24 hours after the last administration)
[0259] As shown in the table above, compared with the blank group, the food intake of rats in the control group 1 was significantly reduced within 24 hours after the last administration (P<0.001); the food intake of rats in the compound 2 group, compound 21 group, compound 25 group, compound 26 group, and compound 27 group within 24 hours after the last administration was basically the same as that of the blank group, with no statistical difference. This proves that the compounds of the present invention are safer and have a lower risk of tissue toxicity.
[0260] The above embodiment is only one of the preferred implementation methods of the present invention and should not be used to limit the scope of protection of the present invention. Any changes or modifications that have no substantive meaning made to the main design concept and spirit of the present invention, as long as the technical problems solved are still consistent with the present invention, should be included in the scope of protection of the present invention.
Claims
1. A compound represented by formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof: in, R 1 is selected from halogen or trifluoromethyl; R 2 Independently selected from NH2, NHR 7 , OH or OR 8 , where: R 7 、R 8 is selected from alkyl or cycloalkyl, R 7 、R 8 The hydrogen in the atom can be replaced by one or more deuterium atoms; R 3 、R 6 independently selected from hydrogen, halogen, alkoxy, haloalkyl or CONH2; R 4 、R 5 independently selected from hydrogen, halogen, alkoxy or haloalkyl; R 9 Independently selected from CH3 or CD3; Among them, except the following compounds:
2. The compound according to claim 1, its stereoisomer or pharmaceutically acceptable salt, characterized in that R 1 selected from chloro or trifluoromethyl; or / and R 2 Independently selected from NH2, NHR 7 ,OH,OR 8 , where: R 7 、R 8 is selected from methyl, ethyl, propyl, cyclopropyl, cyclopropylmethyl or tert-butyl, R 7 、R 8 The hydrogen in the atom can be replaced by one or more deuterium atoms; or / and R 3 、R 6 independently selected from hydrogen, fluorine, chlorine, methoxy, trifluoromethyl or CONH2; or / and R 4 、R 5 independently selected from hydrogen, fluorine, chlorine, methoxy or trifluoromethyl; or / and R 9 Independently selected from CH3 or CD3.
3. The compound according to claim 1, its stereoisomer or pharmaceutically acceptable salt, wherein R 1 Selected from trifluoromethyl; or / and R 2 Independently selected from NH2, NHR 7 , OH or OR 8 , where: R 7 、R 8 is selected from methyl, ethyl, propyl, cyclopropyl, cyclopropylmethyl or tert-butyl, R 7 、R 8 The hydrogen in the atom can be replaced by one or more deuterium atoms; or / and R 3 、R 6 independently selected from hydrogen, fluorine, chlorine, methoxy, trifluoromethyl or CONH2; or / and R 4 、R 5 independently selected from hydrogen, fluorine or chlorine; or / and R 9 Independently selected from CH3 or CD3.
4. The compound according to any one of claims 1 to 3, its stereoisomer or pharmaceutically acceptable salt, wherein: R 1 Selected from trifluoromethyl; or / and R 2 Independently selected from NH2, NHCH3, NHCD3, OH, OCH3, OCD3 or OC(CH3)3; or / and R 3 、R 6 independently selected from fluoro, chloro, methoxy or trifluoromethyl; or / and R 4 、R 5 independently selected from hydrogen, fluorine or chlorine; or / and R 9 Independently selected from CH3 or CD3.
5. The compound according to any one of claims 1 to 4, its stereoisomer or pharmaceutically acceptable salt, wherein: The compound is selected from the following structures:
6. The compound according to any one of claims 1 to 5, its stereoisomer or pharmaceutically acceptable salt, wherein: The hydrogen atoms in the compound, its stereoisomers or pharmaceutically acceptable salts may be replaced by one or more deuterium atoms.
7. The compound according to any one of claims 1 to 6, its stereoisomer or pharmaceutically acceptable salt, wherein: The preparation method of the compound comprises the following steps: When R 2 NH2, NHR 7 OR 8 The synthetic route is as follows: where R 1 、R 3 、R 4 、R 5 、R 6 、R 7 、R 8 、R 9 has the same meaning as any one of claims 1 to 6; Step 1: The starting material a undergoes bromination reaction to generate intermediate b; Step 2: Intermediate b undergoes a condensation reaction with starting material c to generate intermediate c; Step 3: Intermediate d undergoes a substitution reaction with compound e to generate a compound of formula (1); When R 2 When it is OH, the synthetic route is as follows: where R 1 、R 3 、R 4 、R 5 、R 6 、R 7 、R 9 has the same meaning as any one of claims 1 to 6; Step 4: Compound f undergoes hydrolysis under alkaline conditions to generate a compound of formula (1).
8. A key intermediate, characterized in that The structure is shown in formula e below: in, R 1 is selected from halogen or trifluoromethyl, R 9 Selected from CH3 or CD3; preferably, the R 1 is selected from halogen or trifluoromethyl, R 9 Selected from CD3.
9. The intermediate according to claim 8, characterized in that The intermediate is selected from the following compounds: 4-(5-chloro-2-(4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-(methoxy-d3)pyridin-2(1H)-one; 4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-5-(methoxy-d3)pyridin-2(1H)-one.
10. A pharmaceutical composition comprising the compound according to any one of claims 1 to 6, its stereoisomers or pharmaceutically acceptable salts, characterized in that: The pharmaceutical composition further comprises pharmaceutically acceptable excipients.
11. Use of the compound according to any one of claims 1 to 6, its stereoisomers or pharmaceutically acceptable salts in the preparation of a medicament for treating and / or preventing diseases associated with FXIa receptor.
12. The use according to claim 9, characterized in that The disease associated with the FXIa receptor is selected from cerebrovascular arterial disease and / or peripheral arterial disease; further preferably, the disease associated with the FXIa receptor is selected from transient ischemic attack (TIA), ischemic stroke, including cardioembolic stroke: for example, stroke caused by atrial fibrillation, non-cardioembolic stroke: for example, lacunar stroke, stroke caused by large artery or small artery disease, or stroke caused by undetermined cause, cryptogenic stroke, embolic stroke, embolic stroke of undetermined origin, or events of thrombotic and / or thromboembolic origin leading to stroke or TIA, and / or conditions of the peripheral arteries leading to peripheral arterial disease, including peripheral arterial occlusion, acute limb ischemia, amputation, reocclusion and restenosis after intervention (such as angioplasty, stent implantation or surgery and bypass), and / or stent thrombosis.
